A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy

Author(s):
Goemans, N.; Mercuri, E.; Belousova, E.; Komaki, H.; Dubrovsky, A.; McDonald, C.M.; Kraus, J.E.; Lourbakos, A.; Lin, Z.N.; Campion, G.; Wang, S.X.; Campbell, C.; DEMAND III Study Grp
Published
2018
Publication type
Article / Letter to editor
Duchenne muscular dystrophyDrisapersenDystrophinAntisense oligonucleotideExon skippingsix-minute walking distance
Date issued
2018-01-31
Language
English
Is part of
Neuromuscular Disorders (2018), Vol. 28, no. 1, p. 4-15
hdl
1887/86769
doi
10.1016/j.nmd.2017.10.004